GlassScriptPhysician profile
Erin Rudiak
NPI 1013540319
$2,691.63
in general payments reported to CMS, 2019-2025
21 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $428 · 2024: $1,174 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,691.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $506.05 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $443.17 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $442.70 | 2023-2025 | |
| Pfizer INC. | $265.54 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $177.01 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $170.01 | 2023-2025 | Kisunla, Jardiance, Zepbound |
| Astellas Pharma US INC | $157.94 | 2023-2024 | Veozah |
| Daiichi Sankyo INC. | $154.73 | 2023-2025 | Injectafer |
| Exact Sciences Corporation | $65.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.73 | 2025 | Caplyta |
| Merz North America, INC. | $40.29 | 2024 | |
| Medtronic, INC. | $27.56 | 2023 | Intellis Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.00 | 2025 | Jardiance |
| Corcept Therapeutics | $24.77 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $22.83 | 2025 | Inspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $22.56 | 2025 | Bd Max System, Bd Max Instrument |
| Phathom Pharmaceuticals, INC. | $20.91 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $20.29 | 2025 | Auvelity |
| Abbott Laboratories | $19.76 | 2025 | Freestyle Libre 3 |
| Seqirus USA INC | $17.72 | 2024 | Fluad, Flucelvax |
| Glaxosmithkline, LLC. | $16.32 | 2024 | Bexsero, Pediarix, Rotarix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Rudiak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.